Quetiapine and buspirone both elevate cortical levels of noradrenaline and dopamine in vivo, but do not have synergistic effects

Frontiers in Psychiatry

Volumn 3, Issue SEP, 2012, Pages

  Silverstone, P H ^a   Lalies, M D ^a   Hudson, A L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

5HT1A; Buspirone; Cognitive; Dopamine; Microdialysis; Noradrenaline; Quetiapine; Schizophrenia

Indexed keywords

BUSPIRONE; DOPAMINE; NORADRENALIN; QUETIAPINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG EFFECT; FRONTAL CORTEX; IN VIVO STUDY; MALE; MONOTHERAPY; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENALIN RELEASE; RAT; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; TREATMENT DURATION;

EID: 84867132012     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2012.00082     Document Type: Article

References (32)

1. Aleman, A., Hijman, R., De Haan, E. H. F., and Kahn, R. S. (1999). Memory impairment in schizophrenia: a meta-analysis. Am. J. Psychiatry 156, 1358-1366.
2. Astier, B., Lambás-Señas, L., Soulière, F., Schmitt, P., Urbain, N., Rentero, N., Bert, L., Denoroy, L., Renaud, B., Lesourd, M., Muñoz, C., and Chouvet,G. (2003). In vivo comparison of two 5-HT1A receptors agonists alnespirone (S-20499) and buspirone on locus coeruleus neuronal activity. Eur. J. Pharmacol. 459, 17-26.
3. Dalley, J. W., Mason, K., and Stanford, S. C. (1996). Increased levels of extracellular noradrenaline in the frontal cortex of rats exposed to naturalistic environmental stimuli: modulation by acute systemic administration of diazepam or buspirone. Psychopharmacology 127, 47-54.
4. Depoortère, R., Auclair, A. L., Bardin, L., Colpaert, F. C., Vacher, B., and Newman-Tancredi, A. (2010). F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur. Neuropsychopharmacol. 20, 641-654.
5. Elsworth, J. D., Groman, S. M., Jentsch, D. J., Valles, R., Shahid, M., Wong, E., Marston, H., and Roth, R. H. (2012). Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacology 62, 1442-1452.
6. Ghaleiha, A., Noorbala, A. A., Farnaghi, F., Hajiazim, M., and Aljpmdzadeh, S. (2010). A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. J. Clin. Psychpharmacol. 30, 678-682.
7. Gobert, A., Rivet, J. M., Cistarelli, L., Melon, C., and Millan, M. J. (1999). Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 93, 1251-1262.
8. Guo, X., Zhai, J., Wei, Q., Twamley, E. W., Jin, H., Fang, M., Hu, M., and Zhao, J. (2011). Neurocognitive effects of firstand secondgeneration antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci. Lett. 503, 141-146.
9. Hudson, A. L., Lalies, M. D., and Silverstone, P. H. (2012). Venlafaxine enhances the effect of bupropion on extracellular dopamine in rat frontal cortex. Can. J. Physiol. Pharmacol. 90, 803-809.
10. Ichikawa, J., Li, Z., Dai, J., and Melzer, H. Y. (2002). Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 956, 349-357.
11. Johnson-Selfridge, M., and Zalewski, C. (2001). Moderator variables of executive functioning in schizophrenia: meta-analytic findings. Schizo- phr. Bull. 27, 305-316.
12. Lee, J., and Park, S. (2005). Working memory impairments in schizophrenia: a meta-analysis. J. Abnorm. Psychol. 114, 599-611.
13. McGurk, S. R., Carter, C., Goldman, R., Green, M. F., Marder, S. R., Xie, H., Schooler, N. R., and Kane, J. M. (2005). The effects of clozapine and risperidone on spatial working memory in schizophrenia. Am. J. Psychiatry 162, 1013-1016.
14. McLean, S. L., Woolley, M. L., Thomas, D., and Neill, J. C. (2009). Role of 5-HT receptor mechanisms in subchronic PCP-induced reversal learning deficits in the rat. Psychopharma- cology (Berl.) 206, 403-414.
15. Meltzer, H. Y., and Huang, M. (2008). In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog. Brain Res. 172, 177-197
16. Meltzer,H.Y.,and McGurk,S. R. (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizo- phr. Bull. 25, 233-255.
17. Meltzer, H. Y., and Sumiyoshi, T. (2008). Does stimulation of 5-HT1A receptors improve cognition in schizophrenia? Behav. Brain Res. 195, 98-102.
18. Meltzer, H. Y., Horiguchi, M., and Massey, B. W. (2011). The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psy- chopharmacology (Berl.) 213, 289-305
19. Newman-Tancredi, A. (2010). The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr. Opin. Investig. Drugs 11, 802-812.
20. Pira, L., Mongeau, R., and Pani, L. (2004). The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur. J. Pharmacol. 504, 61-64.
21. Piškulic, D., Olver, J. S., Maruff, P., and Norman, T. R. (2009). Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist. Hum. Psychopharmacol. 24, 437-446.
22. Pisu, C., Pira, L., and Pani, L. (2010). Quetiapine anxiolytic-like effect in the Vogel conflict test is serotonin dependent. Behav. Pharmacol. 21, 649-653.
23. Riedel, M., Müller, N., Spellmann, I., Engel, R. R., Musil, R., Valdevit, R., Dehning, S., Douhet, A., Cerovecki, A., Strassnig, M., and Möller,H. J. (2007). Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 257, 402-412.
24. Riedel, M., Schennach-Wolff, R., Musil, R., Dehning, S., Cerovecki, A., Opgen-Rhein, M., Matz, J., Seemüller, F., Obermeier, M., Engel, R. R., Müller, N., Möller, H. J., and Spellmann, I. (2010). Neurocognition and its influencing factors in the treatment of schizophreniaeffects of aripiprazole, olanzapine, quetiapine and risperidone. Hum. Psychopharmacol. 25, 116-125.
25. Routledge, C., Gurling, J., Wright, I. K., and Dourish, C. T. (1993). Neurochemical profile of the selective and silent 5-HT1A receptor antagonist WAY100135: an in vivo microdialysis study. Eur. J. Pharmacol. 239, 195-202.
26. Sumiyoshi, T., Bubenikova-Valesova, V., Horacek, J., and Bert, B. (2008). Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognitionenhancing therapeutics. Adv. Ther. 25, 1037-1056.
27. Sumiyoshi, T., Matsui, M., Nohara, S., Yamashita, I., Kurachi, M., Sumiyoshi, C., Jayathilake, K., and Meltzer, H. Y. (2001). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psy- chiatry 158, 1722-1725.
28. Sumiyoshi, T., Matsui, M., Yamashita, I., Nohara, S., Uehara, T., Kurachi, M., and Meltzer, H. Y. (2000). Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J. Clin. Psychopharmacol. 20, 386-388.
29. Sumiyoshi, T., Park, S., Jayathilake, K., Roy, A., Ertugrul, A., and Meltzer, H. Y. (2007). Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebocontrolled study. Schizophr. Res. 95, 158-168.
30. Sumiyoshi, T., Stockmeier, C. A., Overholser, J. C., Dilley, G. E., and Meltzer, H. Y. (1996). Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Res. 708, 209-214.
31. Yamamura, S., Ohoyama, K., Hamaguchi,T.,Kashimoto,K.,Nakagawa, M., Kanehara, S., Suzuki, D., Matsumoto, T., Motomura, E., Shiroyama, T., and Okada, M. (2009). Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology (Berl.) 206, 243-258.
32. Yatham, L. N., Goldstein, J. M., Vieta, E., Bowden, C. L., Grunze, H., Post, R. M., Suppes, T., and Calabrese, J. R. (2005). Atypical antipsychotics in bipolar depression: potential mechanisms of action. J. Clin. Psychiatry 66(Suppl. 5), 40-48.